United Therapeutics Corporation: revenue
Revenue for United Therapeutics Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All United Therapeutics Corporation financial histories
What this measure means
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
Exact concept: us-gaap:Revenues. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2008-01-01 to 2020-12-31. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2020-01-01 | 2020-12-31 | 1,483,300,000 | USD | 2021-02-24 | 10-K · 0001082554-21-000008 |
| 2019-01-01 | 2019-12-31 | 1,448,800,000 | USD | 2021-02-24 | 10-K · 0001082554-21-000008 |
| 2018-01-01 | 2018-12-31 | 1,627,800,000 | USD | 2021-02-24 | 10-K · 0001082554-21-000008 |
| 2017-01-01 | 2017-12-31 | 1,725,300,000 | USD | 2020-02-26 | 10-K · 0001104659-20-025009 |
| 2016-01-01 | 2016-12-31 | 1,598,800,000 | USD | 2019-02-27 | 10-K · 0001047469-19-000724 |
| 2015-01-01 | 2015-12-31 | 1,465,800,000 | USD | 2018-02-21 | 10-K · 0001047469-18-000911 |
| 2014-01-01 | 2014-12-31 | 1,288,500,000 | USD | 2017-02-22 | 10-K · 0001047469-17-000802 |
| 2013-01-01 | 2013-12-31 | 1,116,984,000 | USD | 2016-02-25 | 10-K · 0001047469-16-010392 |
| 2012-01-01 | 2012-12-31 | 916,076,000 | USD | 2015-02-24 | 10-K · 0001047469-15-001069 |
| 2011-01-01 | 2011-12-31 | 743,183,000 | USD | 2014-02-25 | 10-K · 0001047469-14-001267 |
| 2010-01-01 | 2010-12-31 | 592,899,000 | USD | 2013-02-26 | 10-K · 0001047469-13-001660 |
| 2009-01-01 | 2009-12-31 | 358,880,000 | USD | 2012-02-28 | 10-K · 0001047469-12-001646 |
| 2008-01-01 | 2008-12-31 | 281,497,000 | USD | 2011-02-24 | 10-K · 0001047469-11-001229 |
Related financial histories
- United Therapeutics Corporation: total assets
- United Therapeutics Corporation: total liabilities
- United Therapeutics Corporation: stockholders equity
- United Therapeutics Corporation: cash and cash equivalents
- United Therapeutics Corporation: net income or loss
- United Therapeutics Corporation: operating cash flow
- United Therapeutics Corporation: capital expenditure payments
- United Therapeutics Corporation: contract revenue excluding tax
- United Therapeutics Corporation: financing cash flow
- United Therapeutics Corporation: investing cash flow
- United Therapeutics Corporation: retained earnings or deficit
- United Therapeutics Corporation: basic weighted-average shares
- United Therapeutics Corporation: diluted weighted-average shares
- United Therapeutics Corporation: basic earnings per share
- United Therapeutics Corporation: diluted earnings per share
- United Therapeutics Corporation: income tax expense or benefit
- United Therapeutics Corporation: net property, plant and equipment
- United Therapeutics Corporation: share-based compensation expense
- United Therapeutics Corporation: operating income or loss
- United Therapeutics Corporation: current assets
- United Therapeutics Corporation: interest expense
- United Therapeutics Corporation: current liabilities
- United Therapeutics Corporation: current accounts payable
- United Therapeutics Corporation: goodwill carrying amount
- United Therapeutics Corporation: net finite-lived intangible assets
- United Therapeutics Corporation: net current accounts receivable
- United Therapeutics Corporation: common-stock repurchase payments
- United Therapeutics Corporation: net inventory
- United Therapeutics Corporation: gross profit
- United Therapeutics Corporation: selling, general and administrative expense
- United Therapeutics Corporation: research and development expense
Inspect the source
- Entity
- United Therapeutics Corporation / CIK 0001082554
- Captured
- 2026-09-20T05:20:46.268Z
- SEC response SHA-256
d0d5a14871c4fdbecaf0010c9b80c4651b227dba727aa3a0aedb0042bd1ae9c3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001082554.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))